CUREVAC NV (5CV.DE) Stock Fundamental Analysis
Europe • Frankfurt Stock Exchange • FRA:5CV • NL0015436031
3.892 EUR
+0.01 (+0.36%)
Last: Jan 5, 2026, 07:00 PM
5CV gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 84 industry peers in the Biotechnology industry. 5CV has an average financial health and profitability rating. 5CV has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year 5CV has reported negative net income.
- 5CV had a negative operating cash flow in the past year.
- In the past 5 years 5CV reported 4 times negative net income.
- In multiple years 5CV reported negative operating cash flow during the last 5 years.
1.2 Ratios
- The Return On Assets of 5CV (11.31%) is better than 84.34% of its industry peers.
- With an excellent Return On Equity value of 14.79%, 5CV belongs to the best of the industry, outperforming 84.34% of the companies in the same industry.
- With an excellent Return On Invested Capital value of 14.12%, 5CV belongs to the best of the industry, outperforming 87.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.31% | ||
| ROE | 14.79% | ||
| ROIC | 14.12% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Profit Margin, with a value of 182.11%, 5CV belongs to the top of the industry, outperforming 98.80% of the companies in the same industry.
- With an excellent Operating Margin value of 212.01%, 5CV belongs to the best of the industry, outperforming 98.80% of the companies in the same industry.
- 5CV has a Gross Margin of 93.01%. This is amongst the best in the industry. 5CV outperforms 86.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 212.01% | ||
| PM (TTM) | 182.11% | ||
| GM | 93.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), 5CV is creating value.
- Compared to 1 year ago, 5CV has about the same amount of shares outstanding.
- Compared to 5 years ago, 5CV has more shares outstanding
- The debt/assets ratio for 5CV has been reduced compared to a year ago.
2.2 Solvency
- 5CV has an Altman-Z score of 4.17. This indicates that 5CV is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of 5CV (4.17) is better than 73.49% of its industry peers.
- 5CV has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
- With a decent Debt to Equity ratio value of 0.03, 5CV is doing good in the industry, outperforming 69.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.17 |
ROIC/WACC1.96
WACC7.19%
2.3 Liquidity
- A Current Ratio of 3.70 indicates that 5CV has no problem at all paying its short term obligations.
- 5CV has a better Current ratio (3.70) than 69.88% of its industry peers.
- 5CV has a Quick Ratio of 3.69. This indicates that 5CV is financially healthy and has no problem in meeting its short term obligations.
- With a decent Quick ratio value of 3.69, 5CV is doing good in the industry, outperforming 73.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.7 | ||
| Quick Ratio | 3.69 |
3. Growth
3.1 Past
- The earnings per share for 5CV have decreased strongly by -247.92% in the last year.
- The Revenue for 5CV has decreased by -86.98% in the past year. This is quite bad
- The Revenue has been growing by 98.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-247.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.33%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%
3.2 Future
- Based on estimates for the next years, 5CV will show a very negative growth in Earnings Per Share. The EPS will decrease by -22.50% on average per year.
- 5CV is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -11.14% yearly.
EPS Next Y-163.99%
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue Next Year-84.14%
Revenue Next 2Y-55.71%
Revenue Next 3Y-30.85%
Revenue Next 5Y-11.14%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- 5CV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 5CV. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 5CV indicates a rather cheap valuation: 5CV is cheaper than 96.39% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 2.92 |
4.3 Compensation for Growth
- 5CV's earnings are expected to decrease with -28.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
5. Dividend
5.1 Amount
- 5CV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:5CV (1/5/2026, 7:00:00 PM)
3.892
+0.01 (+0.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-24 2025-11-24/bmo
Earnings (Next)04-08 2026-04-08/amc
Inst Owners10.45%
Inst Owner ChangeN/A
Ins Owners0.09%
Ins Owner ChangeN/A
Market Cap876.36M
Revenue(TTM)70.74M
Net Income(TTM)128.82M
Analysts74.55
Price Target4.02 (3.29%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.69%
Min EPS beat(2)-39.67%
Max EPS beat(2)30.28%
EPS beat(4)2
Avg EPS beat(4)1.84%
Min EPS beat(4)-39.67%
Max EPS beat(4)35.41%
EPS beat(8)3
Avg EPS beat(8)1.3%
EPS beat(12)5
Avg EPS beat(12)-6.32%
EPS beat(16)8
Avg EPS beat(16)6.13%
Revenue beat(2)1
Avg Revenue beat(2)149.77%
Min Revenue beat(2)-96.47%
Max Revenue beat(2)396.01%
Revenue beat(4)2
Avg Revenue beat(4)82.72%
Min Revenue beat(4)-96.47%
Max Revenue beat(4)396.01%
Revenue beat(8)5
Avg Revenue beat(8)103.01%
Revenue beat(12)5
Avg Revenue beat(12)58%
Revenue beat(16)8
Avg Revenue beat(16)71.24%
PT rev (1m)-2.38%
PT rev (3m)-4.19%
EPS NQ rev (1m)0%
EPS NQ rev (3m)966.6%
EPS NY rev (1m)9.31%
EPS NY rev (3m)2.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)33.33%
Revenue NY rev (1m)19.7%
Revenue NY rev (3m)20.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 12.39 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.01 | ||
| P/tB | 1.04 | ||
| EV/EBITDA | 2.92 |
EPS(TTM)-0.71
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS0.31
BVpS3.87
TBVpS3.76
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.31% | ||
| ROE | 14.79% | ||
| ROCE | 16.62% | ||
| ROIC | 14.12% | ||
| ROICexc | 26.37% | ||
| ROICexgc | 27.79% | ||
| OM | 212.01% | ||
| PM (TTM) | 182.11% | ||
| GM | 93.01% | ||
| FCFM | N/A |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.18 | ||
| Cap/Depr | 28.09% | ||
| Cap/Sales | 7.01% | ||
| Interest Coverage | 66.45 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.7 | ||
| Quick Ratio | 3.69 | ||
| Altman-Z | 4.17 |
F-Score3
WACC7.19%
ROIC/WACC1.96
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-247.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.33%
EPS Next Y-163.99%
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%
Revenue Next Year-84.14%
Revenue Next 2Y-55.71%
Revenue Next 3Y-30.85%
Revenue Next 5Y-11.14%
EBIT growth 1Y13.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-158.29%
EBIT Next 3Y-29.43%
EBIT Next 5Y10.78%
FCF growth 1Y62.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.06%
OCF growth 3YN/A
OCF growth 5YN/A
CUREVAC NV / 5CV.DE FAQ
Can you provide the ChartMill fundamental rating for CUREVAC NV?
ChartMill assigns a fundamental rating of 4 / 10 to 5CV.DE.
What is the valuation status of CUREVAC NV (5CV.DE) stock?
ChartMill assigns a valuation rating of 3 / 10 to CUREVAC NV (5CV.DE). This can be considered as Overvalued.
Can you provide the profitability details for CUREVAC NV?
CUREVAC NV (5CV.DE) has a profitability rating of 5 / 10.
What is the financial health of CUREVAC NV (5CV.DE) stock?
The financial health rating of CUREVAC NV (5CV.DE) is 6 / 10.